Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV 1 infection.
Capacity to produce interleukin-2 (IL-2) was measured in haemophiliacs from a well-defined treated cohort. Patients were selected on the basis of HIV-1 antibody status, mean annual dose of clotting factor and liver disease severity. T-cell subsets and peripheral blood mononuclear cell proliferation to Mycobacterium tuberculosis purified protein derivative (PPD) were also measured. Haemophiliacs had reduced IL-2 production, independent of HIV-1 antibody status, mean annual dose of clotting factor concentrate used and liver disease severity. In HIV-1 antibody positive patients reduced levels correlated with PPD proliferative responses (r = 0.6, P = 0.04) and CD8 + ve (r = 0.5, P = 0.05) but not CD4 + ve cell numbers (r = 0.3, P = 0.2). No such correlations were seen in HIV-1 antibody negative patients. Reduced IL-2 production in HIV-1 antibody negative haemophiliacs was due to a qualitative defect. In HIV-1 positive patients a qualitative defect in T lymphocytes that selectively proliferate in response to PPD was observed. CD4 + ve cell numbers were reduced in HIV-1 positive patients.
Madhok
R
R
University Department of Medicine, Glasgow Royal Infirmary, Scotland.
Gracie
J A
JA
Smith
J
J
Lowe
G D
GD
Forbes
C D
CD
D000328:Adult; D005169:Factor VIII / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000276:immunology*; D015497:HIV-1; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D008297:Male; D011446:Prospective Studies
D007376:Interleukin-2; D005169:Factor VIII